Who founded Neurona Therapeutics?

Neurona Therapeutics was founded by Cory Nicholas.

Who are Neurona Therapeutics's investors?

Neurona Therapeutics's investors include Berkeley Frontier, Iaso Ventures, The Column Group, Viking Global, Ysios Capital, Alexandria, Fidelity Investments, LYFE Capital and 7 more.

How much funding has Neurona Therapeutics raised?

Neurona Therapeutics has disclosed $347.5M raised across 6 rounds.

Where is Neurona Therapeutics headquartered?

Neurona Therapeutics is headquartered in South San Francisco, US.

Neurona Therapeutics

South San Francisco, US · 22 known investors

Find your way into Neurona Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Neurona Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.

Biotech Deep Tech Healthtech

Founders & leadership

Cory NicholasFounder · CEO

James StutzChief Financial Officer / Chief Business Officer

Catherine Priest Chief Development OfficerChief Development Officer of Neurona Therapeutics. Priest has experience in neuroscience and cellular therapeutics development, with background spanning industry, government, and academia, and has led work advancing cellular therapies through IND approval and clinical trials.

Gautam Banik Chief Technology OfficerGautam Banik is Chief Technology Officer of Neurona Therapeutics, where he leads manufacturing and process development for cell therapies. He brings experience in cell line development, bioprocess scale-up, cGMP manufacturing, regulatory filings, and technology transfer across recombinant protein, cell therapy, and gene therapy platforms.

Eduardo Dunayevich Chief Medical OfficerEduardo Dunayevich is a psychiatrist with over two decades of pharmaceutical industry experience spanning psychiatry, neurology, metabolic, and autoimmune disorders across small and large molecule programs from pre-IND through Phase IV, including regulatory submissions and approvals. He has held clinical and executive leadership roles and served on governance, data monitoring, and steering committees.

Arnold KriegsteinNamed on SEC filing

Board

Peter Svennilson Board directorFounder / Managing Partner at The Column Group

Tim KutzkeyBoard director

Ray KelleherBoard director

Leo GuthartBoard director

David Goeddel Board directorPartner Emeritus at The Column Group

Brad MargusBoard director

Investors · 22

Berkeley Frontierlisted by Berkeley FrontierBerkeley

How we know: globenewswire.com · the VCSheet dataset · Not right? Tell us

Iaso Ventureslisted by Iaso VenturesCambridge

How we know: Iaso Ventures's portfolio page · a partner's Signal profile · Not right? Tell us

The Column Grouplisted by The Column GroupSan Francisco · $30M

How we know: The Column Group's portfolio page · board seat on SEC Form D · globenewswire.com · the VCSheet dataset · Not right? Tell us

Viking Globallisted by Viking GlobalStamford

How we know: Viking Global's portfolio page · Not right? Tell us

Ysios Capitallisted by Ysios CapitalBarcelona · $5.4M – $21.6M

How we know: Ysios Capital's portfolio page · biospace.com · the VCSheet dataset · Not right? Tell us

AlexandriareportedPasadena

How we know: globenewswire.com · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: biospace.com · Not right? Tell us

LYFE CapitalreportedMenlo Park

How we know: globenewswire.com · Not right? Tell us

Soleus CapitalreportedGreenwich

How we know: biospace.com · Not right? Tell us

Spur Capital PartnersreportedBoston

How we know: globenewswire.com · Not right? Tell us

SymBiosisreportedBentonville

How we know: globenewswire.com · Not right? Tell us

UCB VenturesreportedBrussels

How we know: globenewswire.com · Not right? Tell us

Viking Global InvestorsreportedStamford

How we know: globenewswire.com · Not right? Tell us

Willett AdvisorsreportedNew York

How we know: globenewswire.com · Not right? Tell us

YK BioventuresreportedBurlingame

How we know: biospace.com · Not right? Tell us

Also in the syndicate · 7

Cormorant Asset ManagementEuclidean CapitalPassaic Capital ManagementSchroders CapitalSphera Biotech Master Fund LPUC InvestmentsYsios Capital Partners

Reported raises · per SEC filings

Form D private placements

$347.5M disclosed across 6 rounds · 2014–2025

▶$101.7MraisedApr 2025 · 46 investors · Biotechnology

Rule 506(b)